Is Tilray a Textbook Value Trap -- or the Most Undervalued Cannabis Stock on the Market?

Tilray Brands has lost over 90% of its value in five years and remains unprofitable despite diversifying into craft brewing, hemp wellness, and pharmaceuticals. While recent U.S. cannabis reclassification to Schedule III could create medical research opportunities, the company faces significant headwinds including weak financial results, stringent regulations, and intense competition. The analyst recommends Green Thumb Industries as a better cannabis investment alternative.